Wedbush Sticks to Its Buy Rating for Disc Medicine (IRON)
Wedbush analyst David Nierengarten maintained a Buy rating on Disc Medicine today and set a price target of $88.00.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nierengarten covers the Healthcare sector, focusing on stocks such as Disc Medicine, Oric Pharmaceuticals, and Cogent Biosciences. According to TipRanks, Nierengarten has an average return of 16.2% and a 50.00% success rate on recommended stocks.
In addition to Wedbush, Disc Medicine also received a Buy from Wells Fargo’s Derek Archila in a report issued today. However, on February 28, TipRanks – OpenAI reiterated a Hold rating on Disc Medicine (NASDAQ: IRON).
Based on Disc Medicine’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $60.53 million. In comparison, last year the company had a GAAP net loss of $29.46 million
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of IRON in relation to earlier this year. Last month, Jean M. Franchi, the CFO of IRON sold 4,075.00 shares for a total of $256,154.50.
Read More on IRON:
Disclaimer & DisclosureReport an Issue
- Disc Medicine price target raised to $79 from $78 at Wells Fargo
- Disc Medicine Implements Restructuring Following FDA Response
- Disc Medicine price target lowered to $83 from $114 at Truist
- Disc Medicine price target raised to $111 from $110 at Stifel
- Disc Medicine: Bitopertin’s De-Risked Path to Approval Supports Buy Rating
